Biodexa Pharmaceuticals PLC is a GB-based company operating in Biotechnology industry. The company is headquartered in Abingdon, Oxfordshire and currently employs 13 full-time employees. The company went IPO on 2014-12-08. Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Follow-Up Questions
Biodexa Pharmaceuticals PLC 'in CEO'su kimdir?
Mr. Stephen Stamp 2019 'den beri şirketle birlikte olan Biodexa Pharmaceuticals PLC 'in Chief Executive Officer 'ıdır.
BDRX hissesinin fiyat performansı nasıl?
BDRX 'in mevcut fiyatı $6.52 'dir, son işlem günde 0% decreased etti.
Biodexa Pharmaceuticals PLC için ana iş temaları veya sektörler nelerdir?
Biodexa Pharmaceuticals PLC Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 3 analist Biodexa Pharmaceuticals PLC için analist derecelendirmeleri gerçekleştirdi, bunlar 3 güçlü al, 3 al, 1 tut, 0 sat ve 3 güçlü sat içermektedir
